Key CCGs, including ARNTL, NPAS2, CRY2, and DBP, acted as potent diagnosis and prognosis biomarkers of glioma patients and rhythmically regulated cancer-related signaling pathways and coexpressed genes to affect drug sensitivity and possible clinic outcomes. Here, CRY2 is linked to glioma.